Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$32.76 - $39.56 $173,791 - $209,865
-5,305 Reduced 3.89%
131,023 $4.58 Million
Q3 2023

Nov 14, 2023

SELL
$15.75 - $26.31 $1,496 - $2,499
-95 Reduced 0.07%
136,328 $2.5 Million
Q1 2023

May 12, 2023

BUY
$18.45 - $27.14 $1,752 - $2,578
95 Added 0.07%
136,423 $2.57 Million
Q4 2022

Feb 14, 2023

SELL
$20.18 - $33.33 $20,180 - $33,330
-1,000 Reduced 0.73%
136,328 $3.36 Million
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $894 - $2,652
105 Added 0.08%
137,328 $1.56 Million
Q2 2021

Aug 16, 2021

BUY
$14.69 - $27.52 $2.02 Million - $3.78 Million
137,223 New
137,223 $3.78 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Wetherby Asset Management Inc Portfolio

Follow Wetherby Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.